Procedural Mandates

For each new patient requesting a hormonal contraceptive, and, at a minimum of every twelve months for each returning patient, the prescribing pharmacist shall: (1) Ask the patient to use and complete the TDH-produced standardized self-screening risk assessment tool. The TDH-produced standardized self-screening risk assessment tool shall be the only self-screening risk assessment tool to be utilized when evaluating a patient’s candidacy for a hormonal contraceptive. The TDH-produced standardized self-screening risk assessment tool shall be made available through the TDH website. The same TDH-approved standardized self-screening risk assessment tool may be incorporated into a pharmacy’s management system’s software. (2) Review the self-screening risk assessment answers and clarify responses with the patient as needed before using professional judgment regarding whether to prescribe a hormonal contraceptive. (3) Dispense a hormonal contraceptive to the patient or refer the patient to a pharmacy that may dispense the hormonal contraceptive, if the pharmacist determines the patient is eligible to receive the medication. Dispensing a hormonal contraceptive or referring the patient to another pharmacy that may dispense a hormonal contraceptive shall occur as soon as practicable after making the determination that the patient is eligible to receive a hormonal contraceptive. PRESCRIBING AND DISPENSING OF HORMONAL CONTRACEPTIVES CHAPTER 1140-15 (4) Counsel the patient on matters contained in Tenn. Comp. R. & Regs. 1140-03-.01(1)(e)1 through 1140-03-.01(1)(e)8 at the time the hormonal contraceptive is prescribed and dispensed. (5) Provide the patient with the FDA-required patient product information document that is included with the hormonal contraceptive and a factsheet which includes, but is not limited to, the indications and contraindications for the use of the drug, the appropriate method for using the drug, the importance of a medical follow-up, and other appropriate information. (6) Advise the patient to consult with the patient’s primary care practitioner or women’s health practitioner. (7) Provide the patient, at the time the hormonal contraceptive is prescribed, with a list which contains contact information for primary care practitioners or women’s health practitioners. In the event it is not practicable to provide contact information at the time the hormonal contraceptive is prescribed, the prescribing pharmacist shall provide contact information for primary care practitioners or women’s health practitioners within seventy-two (72) hours after the contraceptive is prescribed.